SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff and repeated tests of its yearly lows are drawing attention amid concerns about heavy debt, costly financing, refinancing needs and insider selling, alongside broader doubts about AI-infrastructure spending. Traders are split: bears see financing risks as a threat to growth, while bulls point to its backlog and AI partnerships and view the selloff as overdone; analyst upgrades and ARKs buying have not dispelled skepticism.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding alongside semiconductor stocks after a steep, extended selloff, drawing dip buyers who see oversold conditions and continued AI-chip demand as support for a recovery. Others warn the bounce may be temporary, citing concerns about AI investment returns and debt, market uncertainty, and upcoming chip-sector earnings.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a semiconductor selloff, with traders focused on CEO Hock Tans warning that some AI investing resembles gambling and his comments about capital constraints. The remarks and worries about AI spending and financing have fueled bearish sentiment, while other traders see the pullback as a buying opportunity based on Broadcoms AI-chip growth; many also complain that the stock has lagged semiconductor peers.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention amid a steep selloff and worries that its debt-funded AI data-center expansion, heavy capital spending, and weak free cash flow may be difficult to finance as credit costs rise and inflation fuels rate concerns. Bears question whether its backlog and AI demand will translate into cash flow, while bulls argue Oracles cloud business and contracted demand make the pullback an opportunity.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a prolonged post-IPO selloff, with traders citing lockup expirations and insider-share supply, a TD Cowen price-target cut, and concerns about OpenAI customer concentration, scaling, and Nvidia competition. Bears see continued selling pressure, while bulls argue the decline is overdone and point to Cerebras AI-chip technology and backlog.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is drawing attention amid a pullback and tentative rebound in AI and semiconductor stocks, as traders debate whether data-center spending can generate adequate returns and whether financing stress at firms such as CoreWeave signals broader risk. Bulls point to sustained chip demand and upcoming company updates, while bears remain concerned about AI valuations, debt exposure, and competition.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Discussion centers on Starknets quantum-resistance narrative and the possibility of moving from an Ethereum L2 to an independent L1, alongside claims of a quantum-resistant Bitcoin transaction test on mainnet. Bulls see the technology and Bitcoin/privacy applications as catalysts, while skeptics point to past dilution, token unlocks and sharp price swings.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas large equity offering has pressured shares, with traders citing dilution even as the capital is intended to support expansion. The selloff is being debated against the bullish AI and data-center demand outlook, prompting dip-buying while others remain concerned about volatility and the stocks valuation.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Scott Kirbys comments supporting a near-total inheritance tax have drawn sharp criticism, with some traders calling for a boycott of United. The discussion also focuses on the quarterly earnings report and recent share weakness, with traders divided between bearish concerns and potential upside if results and guidance reassure investors.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech and semiconductor rebound after the AI-related selloff has lifted QQQ, with traders debating whether it marks a durable recovery or a short-lived relief bounce. Upcoming megacap earnings and concerns about AI spending, oil prices, and inflation are keeping sentiment divided.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

Reasons to Add STE Stock to Your Portfolio Right Now

STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.

Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challenges.

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.

Bet on These Healthcare ETFs to Benefit From the Aging US Population

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.

Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings?

ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation below historical levels draw investor interest.

Abbott (ABT) Gains As Market Dips: What You Should Know

Abbott (ABT) closed the most recent trading day at $101.82, moving +2.23% from the previous trading session.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

ABT, FIG, IP Stocks Fell To 52-Week Lows Today: What's Happening?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>ABT stock fell to a 52-week low of $90.29 in intraday trading as weak Covid-19 testing and U.S. pediatric nutrition, and other sectoral concerns weighed on its performance.&nbsp;</li><li>FIG stock fell to a 52-week low of $16.60 in Thursday’s intraday session as concerns over Anthropic’s AI design tool continued to linger.&nbsp;</li><li>IP stock fell to a 52-week low of $29.45 after its first-quarter results failed to meet Wall Street expectations.</li></ul><p>Abbott Laboratories (ABT), Figma Inc. (FIG), and International Paper Co. (IP) stocks were among those that hit fresh intraday lows on Thursday as investors grew skeptical over regulatory concerns, emerging competitive threats, and earnings results.</p><p>Shares of ABT fell about 0.6% at the close and IP stock closed down more than 9%. Meanwhile, FIG shares recovered from intraday lows, closing up about 5%.</p><h2 class="st-heading-2">Sectoral Concerns Weigh On Abbott</h2><p>The global healthcare company’s shares fell to a 52-week low of $90.29 in intraday trading, capping two consecutive months of declines.</p><p>Abbott has been facing pressure from declining demand for Covid-19 testing, market-share losses in pediatric nutrition, and other sectoral headwinds. Recent positive developments, including FDA clearance for its AI-powered coronary imaging platform Ultreon 3.0 Software, and positive data from four trials, have failed to meaningfully revive the stock’s performance.</p><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/abt">ABT stock</a> has remained in the ‘bearish’ territory over the past 24 hours amid ‘high’ message volumes. ABT shares have declined more than 26% this year.</p><h2 class="st-heading-2">Figma Swings On AI Concerns</h2><p><a href="https://stocktwits.com/symbol/FIG">FIG stock</a> fell to a 52-week low of $16.60 in Thursday’s intraday session before recovering to $17.70 at close. Although the design company has been under pressure over concerns around Anthropic’s artificial intelligence tool, retail investors in the company have largely dismissed concerns.</p><p>Meanwhile, according to Koyfin data, 12 analysts covering the stock have a 12-month average price target of $40.25, representing an upside potential of about 127% from the previous close.</p><p>FIG stock has declined nearly 53% this year, but retail traders on Stocktwits remain ‘bullish’ on the stock.</p><h2 class="st-heading-2">International Paper Declines On Weak Results</h2><p><a href="https://stocktwits.com/symbol/ip">IP stock</a> fell to a fresh 52-week low of $29.45 after it posted first-quarter (Q1) results that disappointed Wall Street and retail investors alike.</p><p>JPMorgan said in a note on Thursday that International Paper's Q1 EBITDA of $677 million was 3% below consensus and below its own guidance of $740 million, according to TheFly. The company’s guidance for the following quarter’s EBITDA was also 25% below consensus estimates at the mid-point. The firm said that the Q1 report was "worse than our negative catalyst watch envisioned."</p><p>JPMorgan has a Neutral rating and $46 price target on International Paper shares. Meanwhile, retail sentiment around the stock was ‘bullish’ at the time of writing. IP stock has lost more than 24% this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The illustration shows the US flag, cash dollar banknotes and stock market indicators. Top US firms announced record buybacks this year. (Source: Getty Images)

Abbott Laboratories, Figma, and International Paper declined to yearly lows amid market pressures, AI threat, and weak earnings. 

Figma

International Paper Co.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABT News